Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Sight Sciences, Inc. (SGHT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"Condensed Consolidated Balance Sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 154,515 $ 185,000 Accounts receivable, net of allowance for credit losses of $1,037 and $1,024 at June 30, 2023 and December 31, 2022, respectively 18,103 15,148 Inventory, net 7,907 6,114 Prepaid expenses and other current assets 1,795 3,415 Total current assets 182,320 209,677 Property and equipment, net 1,477 1,571 Operating lease right-of-use assets 1,125 1,614 Other noncurrent assets 367 211 Total assets $ 185,289 $ 213,073 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 2,947 $ 2,688 Accrued compensation 5,720 7,352 Accrued and other current liabilities 5,386 7,777 Total current liabilities 14,053 17,817 Long-term debt 33,607 33,313 Ot...",
"DELIVERING THE POWER OF SIGHT" |
|
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/09/2023 |
8-K
| Regulation FD Disclosure, Other Events Interactive Data |
| 06/02/2023 |
8-K
| Regulation FD Disclosure, Other Events Interactive Data |
| 05/31/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/25/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/08/2023 |
8-K
| Investor presentation |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
8-K
| Investor presentation |
| 03/16/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
8-K
| Quarterly results|
Docs:
|
"SIGHT SCIENCES, INC. Condensed Consolidated Balance Sheets December 31, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 185,000 $ 260,687 Accounts receivable, net 15,148 8,709 Inventory, net 6,114 3,475 Prepaid expenses and other current assets 3,415 4,164 Total current assets 209,677 277,035 Property and equipment, net 1,571 1,454 Operating lease right-of-use assets 1,614 1,495 Other noncurrent assets 211 202 Total assets $ 213,073 $ 280,186 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 2,688 $ 3,351 Accrued compensation 7,352 5,987 Accrued and other current liabilities 7,777 4,166 Total current liabilities 17,817 13,504 Long-term debt 33,313 32,656 Other noncurrent liabilities 1,867 1,919 Total liabilities 52,997 48,079 Commitment..." |
|
| 02/14/2023 |
SC 13G/A
| Badawi Paul reports a 11.8% stake in Sight Sciences, Inc. |
| 02/14/2023 |
SC 13G/A
| HEP Partners LLC reports a 1.3% stake in Sight Sciences, Inc. |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/09/2023 |
8-K
| Investor presentation |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results|
Docs:
|
"SIGHT SCIENCES, INC. Condensed Consolidated Balance Sheets September 30, December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 199,819 $ 260,687 Accounts receivable, net 12,593 8,709 Inventory, net 5,520 3,475 Prepaid expenses and other current assets 4,411 4,164 Total current assets 222,343 277,035 Property and equipment, net 1,568 1,454 Operating lease right-of-use assets 1,121 1,495 Other noncurrent assets 202 202 Total assets $ 225,234 $ 280,186 Liabilities, redeemable convertible preferred stock, and Stockholders’ equity Current liabilities: Accounts payable $ 3,239 $ 3,351 Accrued compensation 7,993 5,987 Accrued and other current liabilities 6,154 4,166 Total current liabilities 17,386 13,504 Long-term debt 33,158 32,656 Other noncurrent liabilities 1,751 1,919 ..." |
|
| 08/23/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/19/2022 |
SC 13D/A
| Encrantz Staffan reports a 10.9% stake in Sight Sciences, Inc. |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2022 |
8-K
| Other Events Interactive Data |
|
|
|